We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Innovative Operating Platform Supports Incisionless Surgery

By HospiMedica International staff writers
Posted on 06 Apr 2010
An incisionless operating platform (IOP) includes tools that allow physicians to operate without performing external incisions.

The USGI IOP is intended for incisionless surgery procedures, which encompass Natural Orifice Translumenal Endoscopic Surgery (NOTES) and endolumenal and single-port techniques. More...
The platform can also used in bariatric surgery, cholecystectomy, appendectomy, gastrointestinal cancer, Gastroesophageal Reflux Disease (GERD), and urological and gynecological procedures.

The system combines the flexibility of endoscopy with the therapeutic benefit of laparoscopy, offering a stable operating platform, an access port for multiple, robust, flexible surgical tools, and durable tissue anchors to approximate and permanently affix tissue. The elements of the system include the Transport Multi-lumen Access Platform, the g-Lix Helical endoscopic tissue grasper, the g-Prox grasping/tissue approximation device, and the g-Cath tissue-anchor delivery catheters with expandable tissue anchors. The USGI IOP is a product of USGI Medical (San Clemente, CA, USA), and has received both the U.S. Food and Drug Administration (FDA) and the European Community (CE) Marking.

"I've been using USGI's Expandable Tissue Anchoring system for over three years, both in the lab and clinically. It is a superb technology and by far the most durable available for endoscopic tissue approximation,” said Lee Swanstrom, M.D., a professor of surgery at Oregon Health Sciences University (OHSU, Portland, OR, USA). "In my view, this is an essential tool for advanced endoscopists interested in the future of minimally invasive surgery, answering many of the remaining questions about secure endolumenal wound closure and permanent tissue remodeling.”

"Gaining CE Mark approval is a significant step forward in our commercialization of the IOP,” said Eugene Chen, president and CEO of USGI Medical. "We look forward to building long term relationships with European physicians, much like those we have developed with leading surgeons, surgical endoscopists, and gastroenterologists in the U.S. We plan to leverage the versatility of the IOP and the durability of the IOP Expandable Tissue Anchors in various incisionless procedures, with an initial focus on bariatrics in Europe.”

Related Links:

USGI Medical
Oregon Health Sciences University




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.